CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC reports a Return on Equity (ROE) of -94.31%.

What is CELZ's dividend yield?

CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC offers a dividend yield of 0.00%.

What is CELZ's Quality Score?

Our AI rates CELZ's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CELZ?

Our AI Timing Score for CELZ is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CELZ belong to?

CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

CELZ (NASDAQ) Stock Analysis | CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

CELZ AI Analysis Summary

Our AI summary for CELZ: CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -94.31%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CELZ

CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 0.66

-0.10 (-13.12%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-94.3%

ROE

-89.5%

ROA

0.00%

Div Yield

CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.66 Price -0.10 (-13.12%) Day Change	NEWS SCORE: 98

CELZ, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.66
PBV / Sector	0.81 / 5.20 GREAT
Earning Per Share	-0.77

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	0.26 M GREAT
Average 1W Daily Value	0.12 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-192,066.27 / 98.71
NPM Average (%) / Sector	-82,422.55 / -1,721.76
NPM Change Average (%) / Sector	147.59 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-89.46 / 27.02
ROA Average (%) / Sector	-70.16 / -368.17
ROA Change Average (%) / Sector	17.50 / 5,404.12 GOOD
ROE (%) / Sector	-94.31 / 3.47
ROE Average (%) / Sector	-75.15 / 6.51
ROE Change Average (%) / Sector	14.93 / 2,128.13 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:37
Symbol	CELZ
Name	CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	6.49 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	4.96 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 211 East Osborn Road, Phoenix, AZ, United States, 85012

Phone: 480 399 2822

Website: https://www.creativemedicaltechnology.com

Sector: Healthcare >> Biotechnology

Description: Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.